trial · primary record
Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles
Osteosarcoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 530 |
| Primary completion | 2036-01 |
| Primary endpoint | Part 1 of the study (Registration at diagnosis) : event-free survival (EFS)rate of the cohort overall different treatment sequences (First line of treatment) during 3 years . |
| Registry ID | NCT07871864 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:15.527Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07871864
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.